CDK19 is one of the components of the mediator coactivation complex. Mediator complexes are multiprotein complexes required for transcriptional activation by DNA-binding transcription factors of genes transcribed by RNA polymerase II. This gene encodes a protein similar to cyclin-dependent kinase 8, which can also be a component of the mediator complex. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Cyclin-dependent kinase 19 (CDK19) is a cyclin-dependent transcriptional regulatory kinase. CDK19 or CDK8 can form mediator coactivation complexes with three other proteins, CCNC, MED12 and MED13. CDK19 or CDK8 reversibly regulate RNA polymerase II to control transcriptional activity. It has been reported that CCDK19 has carcinogenic effects in prostate cancer, colorectal cancer, breast cancer, etc. Now, CD ComputaBio now offers professional CDK19 targeting services to meet your research needs.
Target prediction uses specific computational methods to predict the potential targets or pharmacological effects of compounds. The small molecule compounds and inhibitors we involve can be reversely verified through target prediction. Traditional methods include methods based on orientation docking and methods based on molecular fingerprints to calculate similarity.
Protein sequence analysis was used to determine the amino acid sequence of the protein moiety after the interaction of the target CDK19 with the small molecule inhibitor. Amino acid sequences can be used in bioinformatic analysis to predict the structure and possible function of proteins. We offer a variety of tools and techniques for analyzing alignment products and providing sequence comparisons to study their biology.
Antibodies have the specificity to recognize antigens, so the use of antibodies to diagnose and treat diseases is a long-term goal of medical researchers. The combination of antibodies and target antigens is highly specific, effective and safe, and is clinically used for various major diseases such as malignant tumors and autoimmune diseases.CD ComputaBio has extensive knowledge and experience in antibody drug discovery services. We collaborate with many scientists from many biotech companies and research institutions. We have extensive experience in this area and can meet your research needs. Our antibody drug discovery services include:
CD ComputaBio provides professional antibody drug discovery service to meet the specific needs of regular customers on time and according to budget. CD ComputaBio relies on world-class technical expertise, we provide customers with the best quality one-stop antibody drug discovery service, including the development of solutions according to different scientific research needs.
Biological systems are often represented as networks of complex sets of binary interactions or relationships between different entities. Different types of information can be represented in the form of networks in order to model cells. The meaning of nodes and edges used in network representation depends on the type of data used to construct the network. Different types of data also produce different general network characteristics in terms of connectivity, complexity, and structure, where edges and nodes may convey multiple layers of information. The network services we provide include but are not limited to:
We construct RINs to analyze the energies of the interaction of target and small molecule compounds. RIN analysis can provide sophisticated analysis of CDK19 targets and their complexes.
We provide PPI network analysis can help you delve into the details of small molecule interactions with CDK19 targets. PPI network analysis is the establishment of highly specific physical contacts between two or more protein molecules, and these interactions include electrostatic forces, hydrogen bonds, and hydrophobic interactions.